LVIVO-TaVec100
/ Legend Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 03, 2025
The LVIVO-TaVec100 Product in the Treatment of Relapsed/Refractory B-cell Malignancies
(clinicaltrials.gov)
- P1 | N=30 | Recruiting | Sponsor: The First Affiliated Hospital with Nanjing Medical University
New P1 trial • Hematological Malignancies • Oncology
1 to 1
Of
1
Go to page
1